Anixa Biosciences CEO Kumar buys $15,800 in stock

Anixa Biosciences Inc (NASDAQ:ANIX), a $102 million market cap biotechnology company, saw its Chief Executive Officer Amit Kumar report purchasing 5,000 shares of the company’s common stock on July 30, 2025. The shares were bought at a price of $3.16, totaling $15,800. According to InvestingPro data, analysts have set price targets ranging from $7 to $10, suggesting significant upside potential from current levels.

Following the transaction, Kumar directly owns 579,925 shares of Anixa Biosciences Inc. The company maintains a strong financial position with a current ratio of 8.89, indicating robust liquidity. InvestingPro subscribers can access additional insights, including 7 more key financial tips and comprehensive insider trading analysis.

In other recent news, Anixa Biosciences has announced several significant developments related to its cancer vaccine technologies. The Canadian Intellectual Property Office issued a Notice of Allowance for a patent concerning Anixa’s breast cancer vaccine, which the company exclusively licensed from Cleveland Clinic. This patent provides composition-of-matter protection for Anixa’s immunogenic approach to breast cancer prevention and treatment in Canada. Additionally, the United States Patent and Trademark Office will soon issue a new patent for Anixa’s breast cancer vaccine technology, covering novel methods of immunizing patients using an immunogenic composition containing human α-lactalbumin protein.

Moreover, Anixa is set to receive another U.S. patent for its ovarian cancer vaccine technology, which targets the anti-Müllerian hormone receptor, type II (AMHR2), a promising target for ovarian cancer prevention and treatment. In clinical trial news, Anixa has dosed the first patient in the fourth cohort of its Phase 1 trial for a CAR-T therapy targeting recurrent ovarian cancer. This cohort will receive a significantly higher dose, as no dose-limiting toxicities were observed in the previous cohort. These recent developments reflect Anixa’s ongoing efforts to expand its intellectual property portfolio and advance its clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.